4 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
The following table presents information regarding each plan-based award granted to our named executive officers during the fiscal year ended December 31, 2023.
| | | | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards(1) | | | All Other Option Awards: Number of Shares of Securities Underlying Options (#)(2) | | | Exercise or Base Price of Option Awards ($/Share) | | | Grant Date Fair Value of Stock and Option Awards ($)(3) | |||||||||
Name | | | Grant Type | | | Grant Date | | | Threshold ($) | | | Target ($) | | | Maximum ($) | | ||||||||
Bahija Jallal | | | Annual Cash | | | — | | | — | | | 551,250 | | | — | | | — | | | — | | | — |
| | Option | | | 2/16/2023 | | | — | | | — | | | — | | | 259,214 | | | 64.53 | | | 10,299,998 | |
Brian Di Donato | | | Annual Cash | | | — | | | — | | | 174,400 | | | — | | | — | | | — | | | — |
| | Option | | | 2/16/2023 | | | — | | | — | | | — | | | 67,949 | | | 64.53 | | | 2,699,987 | |
David Berman | | | Annual Cash | | | — | | | — | | | 206,000 | | | — | | | — | | | — | | | — |
| | Option | | | 2/16/2023 | | | — | | | — | | | — | | | 90,599 | | | 64.53 | | | 3,599,997 | |
Tina St. Leger | | | Annual Cash | | | — | | | — | | | 135,383 | | | — | | | — | | | — | | | — |
| | Option | | | 2/16/2023 | | | — | | | — | | | — | | | 13,338 | | | 64.53 | | | 529,992 |
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
The following table sets forth information regarding compensation awarded to, earned by or paid to our named executive officers during the years ended December 31, 2023, 2022 and 2021, as applicable:
Name and Principal Position | | | Year | | | Salary(1) ($) | | | | | Option Awards(2) ($) | | | Non-Equity Incentive Plan Compensation(3) ($) | | | All Other Compensation(4) ($) | | | Total ($) | |
Bahija Jallal, Ph.D. Chief Executive Officer | | | 2023 | | | 735,000 | | | | | 10,299,998 | | | 606,375 | | | 37,461 | | | 11,678,834 | |
| 2022 | | | 700,000 | | | | | 6,637,003 | | | 656,250 | | | 15,250 | | | 8,008,503 | |||
| 2021 | | | 700,000 | | | | | 33,543,785 | | | 525,000 | | | 14,500 | | | 34,783,285 | |||
Brian Di Donato(5) Chief Financial Officer | | | 2023 | | | 436,000 | | | | | 2,699,987 | | | 191,840 | | | 26,616 | | | 3,354,443 | |
David Berman, M.D., Ph.D.(5) Executive Vice President, Head of Research & Development | | | 2023 | | | 515,000 | | | | | 3,599,997 | | | 257,500 | | | 24,125 | | | 4,396,622 | |
Tina St. Leger(5) (6) Chief Human Resources Officer | | | 2023 | | | 338,458 | | | | | 529,992 | | | 155,691 | | | 14,976 | | | 1,039,117 |
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
Each named executive officer received the following bonus payment for fiscal year 2023 Company and individual performance:
Named Executive Officer | | | Incentive Amount Based on Scorecard as Percent of 2023 Target | | | Individual Performance Modifier | | | 2023 Incentive Amount Paid | | | 2023 Incentive Amount Paid as Percent of 2023 Target |
Bahija Jallal, | | | 110% | | | N/A(1) | | | $606,375 | | | 110% |
Brian Di Donato | | | 110% | | | 100% | | | $191,840 | | | 110% |
David Berman | | | 110% | | | 114% | | | $257,500 | | | 125% |
Tina St. Leger(2) | | | 110% | | | 105% | | | $155,691 | | | 115% |
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
10.16 | Form of Deed of Indemnity between the Registrant and each of its executive officers | F-1 | 333-252166 | 10.2 | January 15, 2021 | |||||
10.17 | Immunocore Holdings plc 2021 Equity Incentive Plan. and Non-Employee Sub Plan to the Immunocore Holdings plc 2021 Equity Incentive Plan | 20-F | 001-39992 | 4.20 | March 25, 2021 | |||||
10.18 | Registration Rights Agreement, dated July 15, 2022, by and among Immunocore Holdings plc and the investors party thereto | 6-K | 001-39992 | 99.2 | July 20, 2022 | |||||
10.19 | Sales Agreement, dated as of September 9, 2022, by and between the Company and Jefferies LLC | 6-K | 001-39992 | 1.1 | September 9, 2022 | |||||
10.20 | Loan Agreement, dated as of November 8, 2022, among Immunocore Limited, as Borrower, the Registrant, certain additional Credit Parties and Guarantors party thereto, BioPharma Credit PLC, as Collateral Agent, and BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP as Lenders | 6-K | 001-39992 | 99.4 | November 9, 2022 | |||||
16.1 | Letter from KPMG LLP, dated March 1, 2023 | 20-F | 001-39992 | 16.1 | March 1, 2023 | |||||
21.1* | Subsidiaries of the Registrant | |||||||||
23.1* | Consent of Deloitte LLP | |||||||||
23.2* | Consent of KPMG LLP | |||||||||
24.1* | Power of Attorney (incorporated by reference to the signature pages of this Annual Report on Form 10-K). | |||||||||
31.1* | Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |||||||||
31.2* | Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |||||||||
32.1** | Certification by the Principal Executive Officer and the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |||||||||
97.1* | Immunocore Holdings plc Incentive Compensation Recoupment Policy |
- Prev
- 1
- Next